Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Dako's Genetic Test for Breast Cancer Recurrence

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved a genetic test made by Dako Denmark designed to predict if a breast cancer tumor will recur and a patient’s chances of long-term survival, the FDA said yesterday.
 
The TOP2A FISH pharmDx test uses fluorescent in situ hybridization to detect or to confirm abnormalities in the topoisomerase 2 alpha gene, which is involved in DNA replication. Changes in this gene in breast cancer cells can be used to predict likelihood of tumor recurrence or long-term survival of a patient. The FDA said the TOP2A FISH pharmDx is the first test to be approved that targets the TOP2A gene in cancer patients.
 
The FDA has deemed the test suitable for premenopausal patients or those who have other indicators of higher chances of tumor recurrence, such as tumor size or lymph node involvement, or decreased survival.
 
The test was studied in Danish patients who were treated with chemotherapy after removal of breast cancer tumors. That study used data from tumor samples and clinical data from 767 patients with high-risk tumors, and it confirmed that the test was useful in estimating recurrence and survival in women who had received chemotherapy, said the FDA.
 
Dako received the CE mark for the test last summer and has since launched the assay in Europe. A Dako spokesperson said that the firm expects to launch the test in the US in April or May.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.